EUVIMEDEUVIMED entdecken
Crossref

23P Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC)

H.S. Rugo, C. Saavedra Serrano, K.H. Jung, M.L. Telli, A. Sonneblick, E. Nili Gal Yam, J. Zhu, A. Collier, M. Craft, A. Galluzzi, H. Ngo, R. Schwab und 1 weitere

Annals of Oncology · 2026-12 · 37 · S385

DOI: 10.1016/j.annonc.2026.08.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von H.S. Rugo und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Rugo, H., Serrano, C. S., Jung, K., Telli, M., Sonneblick, A., Yam, E. N. G., Zhu, J., Collier, A., Craft, M., Galluzzi, A., Ngo, H., Schwab, R., & Bermejo, B. (2026). 23P Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC). Annals of Oncology, 37, S385. https://doi.org/10.1016/j.annonc.2026.08.032

Vancouver

Rugo H, Serrano CS, Jung K, Telli M, Sonneblick A, Yam ENG, et al. 23P Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC). Annals of Oncology. 2026;37:S385. doi:10.1016/j.annonc.2026.08.032

BibTeX
@article{Rugo2026,
  author = {Rugo, H.S. and Serrano, C. Saavedra and Jung, K.H. and Telli, M.L. and Sonneblick, A. and Yam, E. Nili Gal and Zhu, J. and Collier, A. and Craft, M. and Galluzzi, A. and Ngo, H. and Schwab, R. and Bermejo, B.},
  title = {23P Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC)},
  journal = {Annals of Oncology},
  year = {2026},
  volume = {37},
  pages = {S385},
  doi = {10.1016/j.annonc.2026.08.032}
}
Kostenlos starten →